Business Wire

IARPA Funds Team Involving DNA Script, the Broad Institute, and Harvard University for DNA Data Storage Research and Development

Share

DNA Script today announced that the company and its Molecular Encoding Consortium partners have been awarded a multi-phase contract worth up to

$23 million from the Intelligence Advanced Research Projects Activity’s (IARPA) Molecular Information Storage (MIST) program. The goal of the project is to develop sequence-controlled polymers as the basis for deployable storage technologies that can eventually scale into the exabyte regime and beyond with reduced physical footprint, power and cost requirements relative to conventional storage technologies.

The Molecular Encoding Consortium is led by the Laboratory of Dr. Robert Nicol at the Broad Institute of MIT and Harvard and includes DNA Script and Professor Donhee Ham’s Research Group at Harvard University. The consortium will explore the possibility of integrating a novel enzymatic DNA synthesis technology and next-generation sequencing into a single instrument over the 4-year duration of the program. The consortium plans to collaborate with Illumina to leverage its sequencing-by-synthesis (SBS) technologies for accurate, low cost decoding.

Massive amounts of digital data are generated every day, and emerging technologies such as autonomous cars and artificial intelligence will further increase the need for data storage at unprecedented scales. This causes major challenges to private and public organizations, which currently rely on exabyte-scale data centers that have large footprints, consume megawatts of power and cost hundreds of millions of dollars to build, operate and maintain over their lifetimes. It is expected that the anticipated growth in data storage requirements cannot be addressed by current resource-intensive technologies. Nucleic acid-based systems hold promise to store this information with radically reduced physical footprints, power and cost requirements.

This technology is not mature yet and will require extensive development to be ready to use. IARPA has therefore launched the MIST program to fund initiatives that could turn molecular-based data storage into reality. The Molecular Encoding Consortium is one of these funded projects.

“This contract with IARPA, which is part of the Office of the Director of National Intelligence, in partnership with prestigious partners such as the Broad Institute and Harvard University is a strong recognition of DNA Script’s results and leadership in developing enzymatic template-free nucleic acid synthesis,” said Dr. Thomas Ybert, CEO of DNA Script. “However, it is only the beginning of this ambitious project, which will require us to push current technological limits to bring to life our cutting-edge technology while also delivering an operational solution to one of the most important challenges of our time.”

“This project at the intersection of molecular biology, physics, chemistry, information theory and electrical engineering leverages the multi-disciplinary capabilities of our laboratory, our exceptional consortium partners and the collaborative nature of our Institute,” said Dr. Robert Nicol, Senior Director of Technology Development at the Broad Institute and the consortium’s Principal Investigator. “The objectives set out by IARPA for this four-year program are ambitious and will require scientific innovations, as well as robust and scalable technologies.”

“The Molecular Encoding Consortium integrates the different experiences and expertise of these leading institutions,” said Dr. Donhee Ham, the Gordon McKay Professor of Electrical Engineering and Applied Physics at Harvard University. “My research group will bring expertise in the interface of solid-state electronic chips and biological systems. I am looking forward to working with the consortium team in combining silicon integrated circuit technology with molecular biology and electrochemistry to tackle this very interesting problem.”

“DNA is the ideal way to store information for long periods of time,” said Dr. Mostafa Ronaghi, Chief Technology Officer of Illumina. “We are excited by the opportunity to collaborate with the early pioneers involved in this project and having our SBS chemistry and instruments used to decode the digital information.”

About IARPA
IARPA invests in high-risk, high-payoff research programs to tackle some of the most difficult challenges of the agencies and disciplines in the Intelligence Community. Additional information on IARPA and its research may be found on www.iarpa.gov.

About DNA Script
Founded in 2014 in Paris, DNA Script is the world’s leading company in manufacturing de novo synthetic nucleic acids using an enzymatic technology. The company aims at accelerating innovation in life sciences and technology through rapid, affordable, and high-quality DNA synthesis. DNA Script’s approach leverages nature's billions of years of evolution in synthesizing DNA to enable genome scale synthesis. The Company’s technology has the potential to greatly accelerate the development of new diagnostics, therapeutics, sustainable chemicals production, improved crops and data storage solutions. www.dnascript.co

About the Dr. Donhee Ham Research Group
Established in 2002, one of the major intellectual focuses of Donhee Ham’s research group has been on directly interfacing silicon integrated circuits with biological systems for applications in neuroscience, neurotechnology, and biomolecular spectroscopy. Notably, his group at Harvard Applied Physics in collaboration with Dr. Hongkun Park’s group at Harvard Chemistry has recently developed a silicon electronic chip with a surface nanoelectrode array that can copy the synaptic connectivity of thousands of connected mammalian neurons. http://ham.seas.harvard.edu

About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contact in the US for DNA Script
Seismic
Eric Schubert
415-939-4366
eric@teamseismic.com

Press contact in Europe for DNA Script
ALIZE RP
Caroline Carmagnol
06 64 18 99 59
caroline@alizerp.com

DNA Script Contact
publicrelations@dnascript.com

Illumina Contact
Jen Carroll
jcarroll@illumina.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Verimatrix: Signing of an Agreement for the Sale of XTD Assets (Code and Application Protection) to Guardsquare8.12.2025 18:45:00 EET | Press release

Regulatory News: VERIMATRIX (Euronext Paris: VMX, FR0010291245), a leading provider of user security solutions for a safer connected world, announces the signing of an agreement with Belgium-based Guardsquare, the leading provider of mobile application security, for the sale of its Extended Threat Defense (XTD) assets. Guardsquare, the creators of the open-source optimization tool, ProGuard, offers the most complete mobile application security platform on the market spanning automated testing and multi-layered protection, real time threat monitoring, and app attestation. Guardsquare’s 975+ customers are located in more than 95 countries and represent all major industries. Launched in 2021, Verimatrix's Extended Threat Defence (XTD) business is composed of a group of cybersecurity experts specialised in protecting mobile, web and desktop applications. Using a range of innovative solutions, XTD solutions predict, detect and respond to threats before their targets are compromised. Over th

WNBA Champion Sabrina Ionescu Becomes Global Brand Ambassador for Ant International8.12.2025 18:00:00 EET | Press release

Four-time WNBA All-Star Sabrina Ionescu today becomes a new Global Brand Ambassador for Ant International, a leading global provider of digital payments, digitisation, and financial technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208536426/en/ The partnership is built on a shared commitment to creating a more inclusive and sustainable world through empowering underserved communities and youth groups with sports and technology innovation. It marks an important step in Ant International’s journey to foster growth and expand access to financial tools through innovative technology. Ionescu serves as the first Ant International global brand ambassador from North America. “Sabrina embodies the spirit of perseverance and the passion for excellence that is driving young talents and small businesses around the world to uplift their communities,” said Douglas Feagin, President of Ant International. “As a legend in a spor

SABCS 2025: REVEAL GENOMICS Presents Major Advance in Predicting Brain Metastasis in HER2+ Breast Cancer8.12.2025 17:20:00 EET | Press release

REVEAL GENOMICS, S.L., a Barcelona-based biotechnology company focused on advancing precision oncology through biomarker innovation, announced today the presentation of seven studies at the upcoming San Antonio Breast Cancer Symposium (SABCS) 2025, held December 9–12 in San Antonio, Texas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208979141/en/ These abstracts showcase the growing clinical utility and innovation of the company’s proprietary RNA platform and underscore REVEAL GENOMICS’ commitment to improving outcomes for individuals with breast cancer. Across all studies, REVEAL GENOMICS and its collaborators analyzed more than 1,300 tumor samples from individuals with HER2-positive, ER-negative, and triple-negative breast cancer—one of the most extensive genomic contributions to SABCS 2025. Seven independent studies validate the performance and clinical impact of REVEAL GENOMICS’ precision oncology platform New HER2

NetApp Advances EMEA & LATAM Presence with Appointment of Willem Hendrickx as Customer Demand for AI Accelerates8.12.2025 17:15:00 EET | Press release

NetApp (NASDAQ: NTAP), the intelligent data infrastructure company, today announced the appointment of Willem Hendrickxas Senior Vice President and General Manager, EMEA & LATAM, effective January 5, 2026. Hendrickxwill lead NetApp’s business strategy, go-to-market execution, and partner engagement across Europe, the Middle East, Africa, and Latin America. Reporting to NetApp President César Cernuda, Hendrickx brings a deep regional knowledge and track record of building high-performing teams, further enabling the acceleration of NetApp’s international footprint by helping global customers navigate the evolving demands of hybrid cloud and AI-driven data infrastructure. Hendrickx holds a Master’s degree in Applied Economics from KU Leuven and is based in Brussels, Belgium. “Willem joins NetApp at a pivotal time as customer demand surges for intelligent, AI-driven, cloud-enabled data infrastructure globally,” said César Cernuda, President, NetApp. “This appointment underscores our commit

MediaKind and Harmonic’s Video Business to Combine, Creating a Leading Streaming-Infrastructure Platform8.12.2025 16:37:00 EET | Press release

MediaKind, a global leader in cloud-based video streaming technology, today announced it has entered into an agreement to acquire the Video Business of Harmonic Inc. (NASDAQ: HLIT) for approximately $145 million. Following a French employee works council consultation process, the parties would immediately execute a purchase agreement, and the transaction would be expected to close in the first half of 2026, subject to customary regulatory approvals and closing conditions. The transaction creates a world-class independent SaaS streaming infrastructure provider by combining two established video technology organizations with complementary strengths in SaaS streaming, appliance platforms, and cloud AV workloads. The combined company will serve a blue-chip customer base, generate more than $100 million in annual recurring revenue (ARR), over $150 million in annual appliance revenue, and, as a business 100% focused on video, create an enhanced foundation for long-term growth. Additionally,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye